Stock Scorecard



Stock Summary for Acadia Pharmaceuticals Inc (ACAD) - $16.71 as of 4/26/2024 8:50:41 PM EST

Total Score

11 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ACAD

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ACAD

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ACAD

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for ACAD

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for ACAD

ALPMY: 3 Affordable Pharma Stocks to Buy for Portfolio Gains 4/12/2024 10:12:00 AM
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm 4/1/2024 11:54:00 AM
Why Is Acadia ( ACAD ) Down 23.4% Since Last Earnings Report? 3/28/2024 3:30:00 PM
Stoke Therapeutics ( STOK ) Up on Upbeat Dravet Syndrome Study Data 3/27/2024 12:50:00 PM
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More 3/14/2024 4:07:00 PM
Bitcoin, Ethereum, Dogecoin Surge, Crypto Market Cap Hits $2.5T While MicroStrategy Loads Up On BTC; Tesla's German Factory Back Online After Arson Attack Disrupts Production - Top Headlines Today While US Slept 3/12/2024 4:04:00 PM
Acadia ( ACAD ) Down as Schizophrenia Study on Nuplazid Fails 3/12/2024 3:06:00 PM
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday - Oracle ( NYSE:ORCL ) 3/12/2024 1:17:00 PM
Acadia Plummets After Placebo Effect Torpedoes Schizophrenia Study 3/12/2024 1:12:00 PM
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Oracle ( NYSE:ORCL ) 3/12/2024 12:11:00 PM

Financial Details for ACAD

Company Overview

Ticker ACAD
Company Name Acadia Pharmaceuticals Inc
Country USA
Description ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2023
Next Earnings Date 5/6/2024

Stock Price History

Last Day Price 16.71
Last Day Price Updated 4/26/2024 8:50:41 PM EST
Last Day Volume 1,167,609
Average Daily Volume 1,630,870
52-Week High 33.99
52-Week Low 16.16
Last Price to 52 Week Low 3.40%

Valuation Measures

Trailing PE N/A
Industry PE 79.17
Sector PE 56.64
5-Year Average PE -30.15
Free Cash Flow Ratio 6.28
Industry Free Cash Flow Ratio 12.71
Sector Free Cash Flow Ratio 30.65
Current Ratio Most Recent Quarter 2.42
Total Cash Per Share 2.66
Book Value Per Share Most Recent Quarter 2.62
Price to Book Ratio 6.54
Industry Price to Book Ratio 5.66
Sector Price to Book Ratio 22.15
Price to Sales Ratio Twelve Trailing Months 3.89
Industry Price to Sales Ratio Twelve Trailing Months 5.48
Sector Price to Sales Ratio Twelve Trailing Months 5.17

Share Statistics

Total Shares Outstanding 164,772,000
Market Capitalization 2,753,340,120
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 5.43%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 71.62%
Reported EPS 12 Trailing Months -0.37
Reported EPS Past Year 0.00
Reported EPS Prior Year -0.38
Net Income Twelve Trailing Months -61,286,000
Net Income Past Year -61,286,000
Net Income Prior Year -215,975,000
Quarterly Revenue Growth YOY 69.30%
5-Year Revenue Growth 26.55%

Balance Sheet

Total Cash Most Recent Quarter 438,865,000
Total Cash Past Year 438,865,000
Total Cash Prior Year 416,823,000
Net Cash Position Most Recent Quarter 438,865,000
Net Cash Position Past Year 438,865,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 431,755,000
Total Stockholder Equity Prior Year 400,413,000
Total Stockholder Equity Most Recent Quarter 431,755,000

Options

Put/Call Ratio 4.06
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.94
MACD Signal -1.07
20-Day Bollinger Lower Band 13.73
20-Day Bollinger Middle Band 23.84
20-Day Bollinger Upper Band 33.95
Beta 0.39
RSI 28.29
50-Day SMA 24.57
200-Day SMA 26.13

System

Modified 4/26/2024 4:46:24 PM EST